Comments
Drug firm Glenmark Pharmaceuticals Thursday said it has received tentative approval from the US health regulator for generic Fulvestrant injection used for treatment of advanced breast cancer in postmenopausal women.
Glenmark Pharmaceuticals Inc, USA, has been granted tentative approval by the United States Food & Drug Administration (USFDA) for Fulvestrant injection, 250 mg/5 mL (50 mg/mL), the company said.
The product is a generic version of AstraZeneca Pharmaceuticals LP’s Faslodex injection in the same strength, it added.
The Faslodex injection 250 mg/5 mL (50 mg/mL) brand and all available therapeutic equivalents achieved annual sales of around $533.3 million, Glenmark said.
The company’s current portfolio consists of 148 products authorised for distribution in the US market and 54 abbreviated new drug applications (ANDA’s) pending approval with the USFDA.
The injection is used for treatment of hormone receptor positive, human epidermal growth factor receptor 2 - negative advanced breast cancer in postmenopausal women.
Shares of Glenmark Pharmaceuticals closed down 0.33 per cent at ₹ 638.65 on BSE.
Comments
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.